|Bid||79.00 x 1000|
|Ask||79.48 x 1000|
|Day's Range||78.81 - 79.54|
|52 Week Range||52.83 - 80.19|
|Beta (3Y Monthly)||0.38|
|PE Ratio (TTM)||34.24|
|Forward Dividend & Yield||2.20 (2.78%)|
|1y Target Est||N/A|
Merck & Co Inc said on Thursday it would buy drug developer Immune Design Corp for nearly $300 million, to gain access to its immunotherapy programs. Merck will pay $5.85 in cash for each share of Immune ...
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Merck's (MRK) Keytruda fails a phase III study in second-line advanced hepatocellular carcinoma (HCC). It gets FDA approval for the adjuvant treatment of patients with high-risk stage III melanoma.
Intercept (ICPT) reports positive top-line results from its pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
In a collaboration announced Tuesday, Keytruda will be tested with Torque's T-cell therapy against several cancers.
shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration. Merck said late Tuesday that its Keytruda treatment for patients with advanced liver cancer who were previously treated with systemic therapy did not meet the endpoints for overall survival when compared with placebo plus best supportive care. "While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings from the Phase 2 study, which led to the accelerated approval of KEYTRUDA for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib," said chief medical officer Dr. Roy Baynes.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 19) Alector Inc (NASDAQ: ALEC ) (IPOed early February) ...
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 135,613 shares of MRK on 02/19/2019 at an average price of $80.03 a share.
Merck & Co Inc's cancer drug Keytruda failed a late-stage trial's main goals of slowing disease progression and extending the life of patients with a common type of liver cancer, the company said on Tuesday. The results could hamper prospects for the drug, which had received an accelerated approval from the U.S. Food and Drug Administration in November as a treatment for patients with advanced liver cancer who had been previously treated with Bayer AG's Nexavar. Keytruda, which is approved to treat several forms of cancer including skin and lung cancer, is Merck's biggest drug and brought in revenue of $7.17 billion last year.
Merck & Co. Inc. shares declined in after-hours trading Tuesday after the company announced that a study of its Keytruda drug did not meet its goals. The company said that a study on the effectiveness of the drug for patients with a specific type of liver cancer did not reach its defined goals for survival. Merck is testing the drug on a variety of cancers in a big bet on immunotherapy for cancer. Merck shares dipped slightly more than 1% in the extended session after making the announcement, following a 0.7% decline in the regular session. The stock has gained 40.8% in the past 12 months as the S&P 500 index has gained 1.6%.
Merck & Co Inc NYSE:MRKView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $10.04 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. MRK credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Today I will be providing a simple run through ofRead More...
Merck's (MRK) sBLA looking for approval of Keytruda plus Pfizer's Inlyta for the first-line treatment of the most common type of kidney cancer gets FDA's priority review.
A combination of Merck & Co's immunotherapy Keytruda and Pfizer Inc's Inlyta helped patients with advanced kidney cancer live longer than those receiving and older Pfizer standalone therapy, according to data from a late-stage study presented on Saturday. Nearly 90 percent of patients who received the combination therapy were still alive after 12 months compared with about 78 percent of patients who were alive after a year when treated with the older drug Sutent, data showed. Merck on Monday released interim data from the trial, saying the combination reduced the risk of death by 47 percent compared with Sutent.
Announcement: Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Merck & Co., Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Growth driversOn its fourth-quarter earnings conference call, Merck & Co. (MRK) highlighted its oncology, vaccines, hospital and specialty care, and animal
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Dividend projectionsMerck & Co. (MRK) and GlaxoSmithKline (GSK) reported dividends per share of $1.99 and $2.08, respectively, in 2018.Analysts expect
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Expenses guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for a low- to mid-single-digit YoY (year-over-year) rise
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)EPS guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for non-GAAP (generally accepted accounting principles) EPS
MRK or GSK: Which Is the Better Pharmaceutical Pick This Month?(Continued from Prior Part)Revenue guidance for 2019 On its fourth-quarter earnings conference call, Merck & Co. (MRK) guided for revenue of $43.2 billion–$44.7 billion, a YoY